Navigation Links
Light Sciences Oncology Appoints David P. Holveck to Its Board of Directors
Date:4/7/2008

BELLEVUE, Wash., April 7, 2008 /PRNewswire/ -- Light Sciences Oncology, Inc. (LSO) today announced the appointment of David P. Holveck to its Board of Directors. The appointment increases Board membership to eight.

Holveck, 62, is the President, Chief Executive Officer and a Director of Endo Pharmaceuticals. He is the former President of Johnson & Johnson Development Corp. and a Vice President of Corporate Development with Johnson & Johnson (NYSE: JNJ). Previously, he was President and Chief Executive Officer of Centocor Inc. until its acquisition by Johnson & Johnson in 1999. Prior to joining Centocor, he had held positions at General Electric Company, Corning Glass Works and Abbott Laboratories.

"I am pleased and excited to welcome Dave Holveck to our Board," said Llew Keltner, LSO's President and Chief Executive Officer. "He will be a tremendous asset to our company, especially at such an important time in the company's evolution as we reach key milestones in the late-stage development of our light-activated drug therapy."

"Joining the LSO board is a great opportunity to help guide this dynamic company in its future growth and accomplishment," added Holveck. "Together with the other board members, I hope to ensure that the company's potentially revolutionary therapy finds the best possible pathway into medical practice."

Holveck is a member of the Board of Trustees for The Fund for West Chester University, the Board of Directors of the Eastern Technology Council and Cleveland Clinic's Industrial Advisory Board. He has served as a board member of the Pharmaceutical Research and Manufacturing Association (PhRMA) and the Biotechnology Industry Organization (BIO).

He received a Bachelor of Science degree in education/science from West Chester University.

ABOUT LIGHT SCIENCES ONCOLOGY

Light Sciences Oncology, Inc. (LSO) is developing Light Infusion Therapy(TM) (Litx(TM)), an innovative light-activated drug treatment for solid tumors, to provide safer and more effective treatment to cancer patients. In addition to the Phase III trials underway in hepatocellular carcinoma and colorectal cancer metastatic to the liver, the Company has completed a Phase II clinical trial of Litx in glioma. LSO has widened the scope of potential therapeutic applications for Litx to include benign neoplasms such as benign prostatic hyperplasia (BPH) and uterine fibroids, as well as vascular disease, dermatology, and all other applications of the versatile Litx platform. The Company has positioned itself for growth with a strong portfolio of intellectual property, innovative applications in development, and an exceptionally talented team.

CONTACTS

Robert M. Littauer

Vice President, Chief Financial Officer and Treasurer

425-957-8900

bobl@lsoncology.com

Llew Keltner, M.D., Ph.D.

President and CEO

425-957-8900

dr_llew@lsoncology.com

website: http://www.lsoncology.com

Light Infusion Therapy(TM) and Litx(TM) are trademarks of Light Sciences Oncology, Inc.


'/>"/>
SOURCE Light Sciences Oncology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
3. Safety Profile of TAXUS(R) Liberte(TM) Stent System Highlighted in Worlds Largest Stent Registry
4. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
5. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
6. Access Highlighted in Recent BusinessWeek Article
7. Lighting the Onco-Pipeline, Stem Cell Cancer, and More at Global Cancer Congress, January 28-29, 2008, Tampa
8. Highlights of Economic and Business Growth in the Tampa Bay Region
9. Respironics Acquires Apollo Light Systems, Inc., Expands into Circadian Rhythm Device-Based Therapy Market
10. Americas Heartland Launches Third Season Highlighting Contributions of American Farmers and Ranchers
11. CU researchers shed light on light-emitting nanodevice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers ... 5000 and the 6000i models are higher end machines that use the more unconventional ... spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci has ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... Lawrence, MA (PRWEB) , ... June 23, 2016 ... ... the Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research ... test platform of microbial tests introduced last year,” stated Bob Salter, Vice President ...
Breaking Biology Technology:
(Date:6/20/2016)... 20, 2016 Securus Technologies, a leading ... for public safety, investigation, corrections and monitoring announced ... it has secured the final acceptance by all ... Managed Access Systems (MAS) installed. Furthermore, Securus will ... be installed by October, 2016. MAS distinguishes between ...
(Date:6/15/2016)... New York , June 15, 2016 /PRNewswire/ ... a new market report titled "Gesture Recognition Market by ... and Forecast, 2016 - 2024". According to the report, ... USD 11.60 billion in 2015 and is estimated ... reach USD 48.56 billion by 2024.  ...
(Date:6/9/2016)... June 9, 2016 Paris ... Teleste,s video security solution to ensure the safety of people ... during the major tournament Teleste, an international ... and services, announced today that its video security solution will ... to back up public safety across the country. The system ...
Breaking Biology News(10 mins):